Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40GMU | ISIN: US71880W5013 | Ticker-Symbol: 44R1
NASDAQ
03.10.25 | 17:02
2,410 US-Dollar
+0,84 % +0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHIO PHARMACEUTICALS CORP Chart 1 Jahr
5-Tage-Chart
PHIO PHARMACEUTICALS CORP 5-Tage-Chart

Aktuelle News zur PHIO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.09.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series247King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its...
► Artikel lesen
18.09.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Future Conference289King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary...
► Artikel lesen
15.09.Phio Pharmaceuticals Corp. - 8-K, Current Report5
11.09.Phio Pharmaceuticals Corp. - S-8, Securities to be offered to employees in employee benefit plans10
03.09.Phio Pharmaceuticals Corp. - 8-K, Current Report7
03.09.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference302Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile...
► Artikel lesen
PHIO PHARMACEUTICALS Aktie jetzt für 0€ handeln
15.08.Phio Pharmaceuticals files to sell 1.93M shares for holders6
14.08.Phio Pharmaceuticals GAAP EPS of -$0.454
14.08.Phio Pharmaceuticals Corp. - 10-Q, Quarterly Report3
14.08.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update430Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio...
► Artikel lesen
25.07.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds900King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...
► Artikel lesen
25.07.Phio Pharmaceuticals Corp. - 8-K, Current Report3
25.07.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort850Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025)...
► Artikel lesen
25.07.Phio Pharmaceuticals stock soars after manufacturing agreement3
25.07.Phio Pharmaceuticals stock jumps 24% on partnering with U.S. drug substance manufacturer4
25.07.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance476King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...
► Artikel lesen
07.07.Phio Pharmaceuticals Corp. - 8-K, Current Report6
26.06.Phio Pharma stock maintains buy rating as cancer trial advances9
26.06.Phio Pharmaceuticals Corp. - 8-K, Current Report-
25.06.Phio's PH-762 shows positive safety profile in fourth cohort trial5
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1